Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 80
Semaglutide vs tesamorelin compared
Semaglutide and tesamorelin are both FDA-approved peptides, but their regulatory paths, evidence bases and grey-market exposure could not be more different.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Low-dose semaglutide cuts weight in HARMONY
The HARMONY cohort from China reports 9.9% mean weight loss at 24 weeks on semaglutide 0.5 or 1.0 mg weekly, below the 2.4 mg obesity dose.
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.
BPC-157 in Q2 2026: what actually changed
The FDA removed BPC-157 from Category 2 in April 2026 and scheduled a PCAC review for July. The regulatory pathway shifted. The evidence picture did not.
CJC-1295 Q2 2026: what changed this quarter
CJC-1295 remains unapproved. The FDA's PCAC meets in July 2026 but CJC-1295 is not on its agenda. Two 2026 reviews confirm the clinical evidence has not moved.
Ipamorelin Q2 2026: what changed
Quarterly ipamorelin review: the HHS reclassification announcement, a still-pending FDA Category 1 move, and no new trial data.